Search the Newsreel

DexCom Inc. stock underperforms Friday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.89% to $89.75 on Friday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. This drop ended a six-day winning streak for the company's stock.

Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs

Dexcom director Nicholas Augustinos reported a gift of 1,075 shares of common stock to a charitable donor-advised fund on August 12, 2026. These shares were held indirectly through the Kirschner/Augustinos Revocable Trust, which now holds 37,382 shares. Additionally, Augustinos holds 5,575 unvested restricted stock …

DexCom Inc (MIL:1DXCM) Stock Price, Trades & News

This page provides a detailed overview of DexCom Inc (MIL:1DXCM) stock, including its current price, market capitalization, P/E and P/B ratios, and key financial metrics. It highlights the company's financial strength, growth rank, profitability, and GF Value rank, along with recent news and upcoming …

Die Dexcom-Aktie steigt nach starken Q2-2026-Zahlen und höherer Prognose weiter

Dexcom stock holds above $90 as strong Q2 2026 margins support a raised outlook

Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating

Citigroup has increased its price target for DexCom (DXCM) shares to $105 from $88, while reiterating a Buy rating on the stock. This adjustment reflects a more optimistic outlook from the firm regarding the medical equipment company. DexCom specializes in continuous glucose monitoring systems …

Is DexCom (DXCM) Fully Valued Following Strong Earnings And Higher Revenue Guidance?

DexCom Inc. stock outperforms competitors on strong trading day

DexCom Inc. (DXCM) saw its stock rise by 1.42% to $90.80 on Wednesday, marking its fifth consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04% on …

DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade

DexCom director Bridgette P. Heller sold 1,012 shares of common stock at $88.29 per share on August 12, 2026, as part of a pre-established Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Ms. Heller directly holds 29,570 shares, which includes 5,575 …

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, …

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's …

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, …

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace …

DexCom’s 37.5% quarter puts CGM maker within 3.5% of its high as volume stays moderate

DexCom closed at $84.75 after a ninth week in an active Trend Signal, but participation is only 1.1x baseline and the signal mix is balanced rather than emphatic.

E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB increased its stake in DexCom, Inc. by 18.9% in the second quarter, bringing its total holdings to 113,204 shares valued at $7.62 million. Other institutional investors also adjusted their positions in the medical device company. Insider activity …

Unos resultados más sólidos en el segundo trimestre y unas perspectivas más optimistas para 2026 podrían cambiar los argumentos a favor de invertir en DexCom (DXCM)

Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM)

DexCom (DXCM) reported stronger-than-expected Q2 2026 results with increased sales and net income, and raised its full-year 2026 revenue guidance. This positive performance reinforces management's confidence in the demand for its continuous glucose monitoring systems and supports the adoption-driven catalyst investors are watching. Despite …

DexCom stock hits 52-week high at 87.85 USD By Investing.com

DexCom Inc.'s stock reached a 52-week high of $87.85, reflecting strong investor confidence and market sentiment. The company reported robust second-quarter revenue, surpassing analyst estimates, and raised its guidance for the second consecutive quarter. Analysts from RBC Capital, BTIG, Canaccord, TD Cowen, and Piper …

Assenagon Asset Management S.A. Has $46.72 Million Holdings in DexCom, Inc. $DXCM

Assenagon Asset Management S.A. significantly reduced its stake in DexCom, Inc. by 59.7% in the second quarter, now holding 693,635 shares valued at $46.72 million. Despite this, institutional investors collectively own 97.75% of DXCM, and analysts generally maintain a "Moderate Buy" rating with an …

DexCom, Inc. $DXCM Stock Position Lifted by Gradient Investments LLC

Gradient Investments LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 16.7% in the second quarter, bringing its total holdings to 372,542 shares valued at approximately $25.1 million. DexCom recently reported strong quarterly earnings, beating expectations with $0.70 EPS and a 13.1% year-over-year revenue …

DexCom, Inc. $DXCM Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. significantly reduced its stake in DexCom (NASDAQ:DXCM) by 96.5% in the first quarter, selling 948,754 shares and retaining 34,025 shares. Despite this, institutional investors and hedge funds still own 97.75% of the company, and analyst sentiment remains positive with a "Moderate …

DexCom Inc. Stock Sheds 4.9%, Underperforms Market

The article reports that DexCom Inc. (DXCM) stock experienced a 4.9% decline, leading to its underperformance in the market. The brief notice, sourced from Dow Jones, indicates a negative movement for the company's shares. Further details require a user to log in.

Dexcom Inc (DXCM) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

DexCom Inc (DXCM) draws heavier trading as weekly gain hits 16.6%

The continuous glucose monitoring maker’s 12-week advance now stands at 37.7%, with trend and relative-strength readings still constructive.

DexCom Inc. stock underperforms Wednesday when compared to competitors

DexCom Inc. (DXCM) shares fell 4.92% on Wednesday to close at $82.66, marking its second consecutive day of losses. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The stock's movement was …

Insulet Q2 results pressure Tandem, DexCom (PODD:NASDAQ)

Insulet Corporation's Q2 results, which included a lowered full-year revenue outlook, caused its stock to hit a 52-week low. This downturn also impacted competitors Tandem Diabetes and Dexcom, sending their shares lower. The news suggests a challenging environment for medical technology companies specializing in …

DexCom, Inc. (DXCM) Stock forecasts

Argus has issued an analyst report on DexCom, Inc. (DXCM) with a favorable outlook, citing potential expansion in diabetes coverage. The report, dated August 4, 2026, highlights Dexcom's focus on designing and commercializing Continuous Glucose Monitoring (CGM) systems for diabetes and metabolic health management. …

DexCom Inc (DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan

A family trust associated with DexCom Inc. director Mark G. Foletta sold a total of 4,000 shares of common stock in two transactions on July 31, 2026, and August 3, 2026, under a pre-arranged 10b5-1 Plan. The sales were made at $80.00 and $85.32 …

Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline

Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its glucose monitoring products, …

Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025

Levi & Korsinsky, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made material design changes to its G6 and G7 …

Argus Adjusts Price Target on DexCom to $96 From $86, Maintains Buy Rating

Argus has increased its price target for DexCom (DXCM) to $96 from $86, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook for the medical equipment company specializing in continuous glucose monitoring systems.

DEXCOM INC : ARGUS RESEARCH RAISES TARGET PRICE BY $10 TO $96

Argus Research has increased its target price for Dexcom Inc. (DXCM.O) by $10, raising it to $96. This adjustment reflects an updated outlook from the research firm regarding the medical device company specializing in continuous glucose monitoring systems.

Sei Investments Co. Acquires 38,263 Shares of DexCom, Inc. $DXCM

Sei Investments Co. increased its stake in DexCom, Inc. by 42.4% in the first quarter, adding 38,263 shares to reach a total of 128,467 shares valued at $8.1 million. This increase comes as DexCom reported strong quarterly earnings, beating consensus estimates with $0.70 EPS …